DK1028738T3 - Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser - Google Patents

Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser

Info

Publication number
DK1028738T3
DK1028738T3 DK98957605T DK98957605T DK1028738T3 DK 1028738 T3 DK1028738 T3 DK 1028738T3 DK 98957605 T DK98957605 T DK 98957605T DK 98957605 T DK98957605 T DK 98957605T DK 1028738 T3 DK1028738 T3 DK 1028738T3
Authority
DK
Denmark
Prior art keywords
mitogens
cytokines
immune responses
pathological immune
inhibit pathological
Prior art date
Application number
DK98957605T
Other languages
English (en)
Inventor
David A Uty Of Souther Horwitz
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of DK1028738T3 publication Critical patent/DK1028738T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98957605T 1997-11-05 1998-11-05 Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser DK1028738T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6450797P 1997-11-05 1997-11-05
PCT/US1998/023584 WO1999025366A1 (en) 1997-11-05 1998-11-05 Use of cytokines and mitogens to inhibit pathological immune responses

Publications (1)

Publication Number Publication Date
DK1028738T3 true DK1028738T3 (da) 2003-08-11

Family

ID=22056456

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98957605T DK1028738T3 (da) 1997-11-05 1998-11-05 Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser

Country Status (11)

Country Link
US (1) US6228359B1 (da)
EP (1) EP1028738B1 (da)
JP (1) JP4309047B2 (da)
AT (1) ATE238061T1 (da)
AU (1) AU747767B2 (da)
CA (1) CA2309115C (da)
DE (1) DE69813868T2 (da)
DK (1) DK1028738T3 (da)
ES (1) ES2198774T3 (da)
PT (1) PT1028738E (da)
WO (1) WO1999025366A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
WO1999048524A1 (en) 1998-03-03 1999-09-30 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
DK1173549T3 (da) * 1999-05-05 2008-12-08 Univ Southern California Anvendelse af cytokiner og mitogener til inhibering af pathologisk immun-responser
CA2384418C (en) * 1999-09-01 2008-07-22 University Of Southern California Use of cytokines, cells, and mitogens to inhibit graft versus host disease
WO2001077299A2 (en) 2000-04-11 2001-10-18 University Of Southern California A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
AU2007202534B2 (en) * 2000-04-11 2011-06-09 University Of Southern California A method to prevent graft rejection using TGF-beta to induce T suppressor cells
EP1463799A4 (en) * 2001-12-21 2006-01-18 Univ Southern California PROCESS FOR INDUCTION OF LEARNED AND CYTOKINE-PRODUCING REGULATORY CELLS
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8951796B2 (en) 2010-04-22 2015-02-10 University Of Southern California Methods and compositions for expanding and stabilizing natural regulatory T cells
EP2763692A2 (en) 2011-10-06 2014-08-13 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
US9958456B2 (en) 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
US20150110738A1 (en) 2012-05-04 2015-04-23 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
AU1382799A (en) 1999-06-07
ES2198774T3 (es) 2004-02-01
ATE238061T1 (de) 2003-05-15
US6228359B1 (en) 2001-05-08
JP2001523443A (ja) 2001-11-27
PT1028738E (pt) 2003-08-29
EP1028738A1 (en) 2000-08-23
AU747767B2 (en) 2002-05-23
WO1999025366A1 (en) 1999-05-27
EP1028738B1 (en) 2003-04-23
JP4309047B2 (ja) 2009-08-05
DE69813868D1 (de) 2003-05-28
CA2309115C (en) 2010-10-19
DE69813868T2 (de) 2004-03-04
CA2309115A1 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
DK1028738T3 (da) Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser
EP2371859A3 (en) Treatment of TNF alpha related disorders
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
NO971902D0 (no) Bindingsmidler til CD23
DE69715442T2 (de) Fluorierte triallylisocyanurate, vulkanisierbare elastomerzusammensetzungen die diese enthalten, und vulkanisationsverfahren
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
NO905408D0 (no) Baerer for biomassenitrifiseringsmiddel, nitrifiseringsreaktor og biologisk fremgangsmaate for aerobnitrifisering.
NO881051D0 (no) Metoder for behandling av solskadet, human hud med retinoider.
ES2155834T3 (es) Procedimiento de tratamiento de lesiones o de disminuciones celulares.
MX9303127A (es) Metodo para reducir selectivamente la poblacion celular de leucocitos.
FR2491334B1 (da)
DK0414019T3 (da) Substituerede N-(quinolin-2-yl-methoxy)benzyl-sulfonylurinstoffer
PT77019B (de) Mittel zur behandlung von wunden
DK1173549T3 (da) Anvendelse af cytokiner og mitogener til inhibering af pathologisk immun-responser
BG101126A (en) The use of muramylpeptide compounds
Rachman Psychotherapy of difficult cases: Flexibility and responsiveness in contemporary practice.
EP1291020A3 (en) Use of cytokines and mitogens to inhibit pathological immune responses
DE69012883D1 (de) Methode für die Behandlung von Abgas.
DK410087A (da) Lavviskoese sulfurerede alkylphenoler, overbaserede med gruppe ii metaller
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE261607T1 (de) Biozide mittel zur behandlung gewerblicher abwaesser, insbesondere gaswascherschlaemme.
PT85658A (pt) Aparelhagem para o tratamento de plantas de latada em estufas de bloco
NO963911L (no) Innretning for behandling av autoimmune sykdommer og fremgangsmåte for behandling
DK161886D0 (da) Fremgangsmaade til konservering af raa huder, skind og pelse